Ilyang to file health registration for Ilaprazole in China.
Published: 2005-12-26 06:57:00
Updated: 2005-12-26 06:57:00
Ilyang is conducting a phase III clinical study on Ilaprazole, a new anti-peptic ulcer drug, in China, and intends to apply its NDA probably around February next year for the market launching in the late 2006 under the technical license agreement with Livzon of China.
The peptic ulcer drug m...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
